{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-244260","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.902873+00:00","generated_at":"2026-06-29T13:53:16.492466+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Surrozen completes SPAC merger; Nasdaq listing under SRZN/SRZNW on Aug 12","bullets":["Business combination with Consonance-HFW Acquisition Corp. closed August 11, 2021.","Common stock and warrants start trading on Nasdaq August 12 under SRZN and SRZNW.","Transaction approved by Consonance-HFW shareholders on August 10 and Surrozen stockholders.","Existing management, led by CEO Craig Parker, to continue leading the combined company.","Surrozen focuses on Wnt pathway therapeutics for tissue repair and regeneration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-244260","json":"https://secwatch.observer/filing/0001193125-21-244260.json","markdown":"https://secwatch.observer/filing/0001193125-21-244260.md","text":"https://secwatch.observer/filing/0001193125-21-244260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000119312521244260/0001193125-21-244260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000119312521244260/d148870d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:53:16.492466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}